BBIO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- BridgeBio reports that encaleret increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial for ADH1Oct 12, 2026
- BridgeBio reports significantly better clinical outcomes with acoramidis versus tafamidis in ATTR-CM, according to an independent real-world study of U.S. electronic health recordsOct 12, 2026
- BridgeBio will present new acoramidis data, including independent comparative real-world EHR findings, at the 2026 HFSA Annual Scientific MeetingOct 6, 2026
- BridgeBio receives FDA acceptance and Priority Review for the NDA of oral infigratinib for children with achondroplasiaOct 6, 2026
- BridgeBio reports BBP-418 may have disease-modifying potential, restoring cardiac and disease biomarkers toward unaffected levelsOct 5, 2026